Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-1.34%)
CHF 0.06
(-1.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.31 Million CHF | 49.75% |
| 2022 | -20.52 Million CHF | -32.34% |
| 2021 | -15.5 Million CHF | -26.65% |
| 2020 | -12.24 Million CHF | 17.47% |
| 2019 | -14.83 Million CHF | -941.28% |
| 2018 | -1.42 Million CHF | 55.96% |
| 2017 | -3.23 Million CHF | -3.37% |
| 2016 | -3.12 Million CHF | 19.09% |
| 2015 | -3.86 Million CHF | -115.29% |
| 2014 | -1.79 Million CHF | 87.57% |
| 2013 | -14.45 Million CHF | 46.47% |
| 2012 | -27.01 Million CHF | 12.8% |
| 2011 | -30.97 Million CHF | 7.81% |
| 2010 | -33.59 Million CHF | 21.96% |
| 2009 | -43.05 Million CHF | -73.11% |
| 2008 | -24.87 Million CHF | 33.89% |
| 2007 | -37.62 Million CHF | -80.01% |
| 2006 | -20.9 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -788.09 Thousand CHF | 70.62% |
| 2024 Q2 | -899.31 Thousand CHF | -14.11% |
| 2023 FY | -10.31 Million CHF | 49.75% |
| 2023 Q4 | -2.68 Million CHF | -1.12% |
| 2023 Q3 | -2.65 Million CHF | -4.16% |
| 2023 Q2 | -2.54 Million CHF | -6.14% |
| 2023 Q1 | -2.39 Million CHF | 31.41% |
| 2022 Q1 | -5.76 Million CHF | -34.78% |
| 2022 Q3 | -4.16 Million CHF | 41.25% |
| 2022 FY | -20.52 Million CHF | -32.34% |
| 2022 Q2 | -7.09 Million CHF | -23.07% |
| 2022 Q4 | -3.49 Million CHF | 16.04% |
| 2021 Q1 | -3.14 Million CHF | -67.12% |
| 2021 FY | -15.5 Million CHF | -26.65% |
| 2021 Q2 | -4.5 Million CHF | -43.16% |
| 2021 Q3 | -3.57 Million CHF | 20.65% |
| 2021 Q4 | -4.27 Million CHF | -19.56% |
| 2020 FY | -12.24 Million CHF | 17.47% |
| 2020 Q4 | -1.88 Million CHF | 39.49% |
| 2020 Q3 | -3.11 Million CHF | -4.68% |
| 2020 Q2 | -2.97 Million CHF | 30.4% |
| 2020 Q1 | -4.27 Million CHF | -27.36% |
| 2019 Q3 | -3.76 Million CHF | 13.8% |
| 2019 Q1 | -3.12 Million CHF | -60.91% |
| 2019 FY | -14.83 Million CHF | -941.28% |
| 2019 Q4 | -3.35 Million CHF | 10.81% |
| 2019 Q2 | -4.36 Million CHF | -39.71% |
| 2018 FY | -1.42 Million CHF | 55.96% |
| 2018 Q3 | -1.94 Million CHF | -257.96% |
| 2018 Q2 | 1.22 Million CHF | -0.0% |
| 2018 Q1 | 1.22 Million CHF | 265.71% |
| 2018 Q4 | -1.94 Million CHF | 0.0% |
| 2017 Q3 | -741.61 Thousand CHF | 15.33% |
| 2017 FY | -3.23 Million CHF | -3.37% |
| 2017 Q4 | -741.61 Thousand CHF | 0.0% |
| 2017 Q2 | -875.91 Thousand CHF | 0.0% |
| 2017 Q1 | -875.91 Thousand CHF | -6.35% |
| 2016 Q1 | -741.21 Thousand CHF | -39.79% |
| 2016 FY | -3.12 Million CHF | 19.09% |
| 2016 Q4 | -823.58 Thousand CHF | 0.0% |
| 2016 Q3 | -823.58 Thousand CHF | -11.11% |
| 2016 Q2 | -741.21 Thousand CHF | 0.0% |
| 2015 Q4 | -530.24 Thousand CHF | 0.0% |
| 2015 Q2 | -790.16 Thousand CHF | 0.0% |
| 2015 Q1 | -790.16 Thousand CHF | -1.55% |
| 2015 FY | -3.86 Million CHF | -115.29% |
| 2015 Q3 | -530.24 Thousand CHF | 32.89% |
| 2014 Q1 | -483.49 Thousand CHF | -84.09% |
| 2014 Q4 | -778.1 Thousand CHF | 0.0% |
| 2014 Q3 | -778.1 Thousand CHF | -60.94% |
| 2014 Q2 | -483.49 Thousand CHF | 0.0% |
| 2014 FY | -1.79 Million CHF | 87.57% |
| 2013 Q3 | -262.63 Thousand CHF | 96.23% |
| 2013 Q4 | -262.63 Thousand CHF | 0.0% |
| 2013 FY | -14.45 Million CHF | 46.47% |
| 2013 Q1 | -6.96 Million CHF | -18.87% |
| 2013 Q2 | -6.96 Million CHF | 0.0% |
| 2012 Q3 | -5.86 Million CHF | 0.0% |
| 2012 FY | -27.01 Million CHF | 12.8% |
| 2012 Q4 | -5.86 Million CHF | 0.0% |
| 2011 FY | -30.97 Million CHF | 7.81% |
| 2010 FY | -33.59 Million CHF | 21.96% |
| 2009 FY | -43.05 Million CHF | -73.11% |
| 2008 FY | -24.87 Million CHF | 33.89% |
| 2007 FY | -37.62 Million CHF | -80.01% |
| 2006 FY | -20.9 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BB Biotech AG | -29.92 Million CHF | 65.547% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 153.69% |
| Evolva Holding SA | -92.24 Million CHF | 88.822% |
| Idorsia Ltd | -543.05 Million CHF | 98.101% |
| Kuros Biosciences AG | -13.19 Million CHF | 21.838% |
| Molecular Partners AG | -61.1 Million CHF | 83.126% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 90.696% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 114.978% |